High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study
Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong MF, Jude EB
Nutrients · 112 citations
How it was studied
- Design
- Cross-sectional study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Independent funding
- Government
- National Institute for Health and Care Research
- Government
- National Institute for Health Research (NIHR)
- Grants
- National Institute for Health and Care Research (NIHR-INF-0556)
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2020-12-11 · Nutrients · vol. 12 · issue 12 · p. 3799
- Publisher
- Multidisciplinary Digital Publishing Institute
- Cited
- 175 citations · more than 100% of similar papers · 20.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 23 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Vitamin D Research Studies · COVID-19 Clinical Research Studies · Long-Term Effects of COVID-19
- Keywords
- Medicine, Cholecalciferol, Vitamin D and neurology, vitamin D deficiency, Internal medicine, Retrospective cohort study, Cohort study, Coronavirus disease 2019 (COVID-19), Cohort, Pediatrics, Disease, Infectious disease (medical specialty)
- MeSH
- humans, cholecalciferol, risk factors, cross-sectional studies, aged, aged, 80 and over, middle aged, female, male, united kingdom, covid-19, sars-cov-2, covid-19 drug treatment
7 authors
From GB
- Stephanie Fenxi LingUniversity of Manchester; Tameside and Glossop Integrated Care NHS Foundation Trust
- Eleanor BroadTameside and Glossop Integrated Care NHS Foundation Trust
- Rebecca MurphyTameside and Glossop Integrated Care NHS Foundation Trust
- Joseph M PappachanManchester Metropolitan University; Lancashire Teaching Hospitals NHS Foundation Trust; University of Manchester; Royal Preston Hospital
- Satveer Pardesi-NewtonLeicester Royal Infirmary; University Hospitals of Leicester NHS Trust
- Marie‐France KongLeicester General Hospital; University Hospitals of Leicester NHS Trust
Abstract
The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its "parent" form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (ORadj 0.13, 95% CI 0.05-0.35, p adj 0.38, 95% CI 0.17-0.84, p = 0.018). In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. Further work with large population studies needs to be carried out to determine adequate serum 25(OH)D levels, as well as multi-dose clinical trials of cholecalciferol therapy to assess maximum efficacy.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.